At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
PF-00868554 +4 moredrug
Likely dose
PF-00868554 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers
In Brief
A Phase 1 clinical trial evaluating PF-00868554 and Placebo for Hepatitis C. Completed, enrolled 32 participants across 4 sites in 3 countries.
Detailed Summary
Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesBelgium, Germany, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedMar 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedMar 8, 2007
Enrollment StartJan 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.3 years ago
Interventions
PF-00868554drug
300 mg BID
PF-00868554drug
450 mg BID
PF-00868554drug
100 mg BID
PF-00868554drug
300 mg TID
Placebodrug
Placebo